Cargando…
Oestradiol Contributes to Differential Antitumour Effects of Adjuvant Zoledronic Acid Observed Between Pre- and Post-Menopausal Women
Clinical trials have demonstrated that adding zoledronic acid (Zol) to (neo)adjuvant standard of care has differential antitumour effects in pre- and post-menopausal women: Both benefit from reduced recurrence in bone; however, while postmenopausal women also incur survival benefit, none is seen in...
Autores principales: | Canuas-Landero, Victor G., George, Christopher N., Lefley, Diane V., Corness, Hannah, Muthana, Munitta, Wilson, Caroline, Ottewell, Penelope D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559775/ https://www.ncbi.nlm.nih.gov/pubmed/34733240 http://dx.doi.org/10.3389/fendo.2021.749428 |
Ejemplares similares
-
Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions
por: George, Christopher N., et al.
Publicado: (2020) -
Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid
por: Lefley, DV, et al.
Publicado: (2008) -
Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid
por: Ottewell, PD, et al.
Publicado: (2008) -
The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway
por: Wilson, Caroline, et al.
Publicado: (2015) -
The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells
por: Brown, Hannah K, et al.
Publicado: (2011)